ASCO 2024: Immunotherapy for the Treatment of Small Cell Lung Cancer - Episode 3

cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC

, , ,

Tarita O. Thomas, MD, PhD discusses patients with LS-SCLC, and what she would consider to be a reasonable time interval between completion of cCRT to initiation of consolidation therapy with a PD-L1 inhibitor. The panel also discusses the potential for curative-intent immunotherapy with durvalumab for earlier stages of SCLC.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer
    EP. 2: ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC
    Now Viewing
    EP. 3: cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC
    EP. 4: Examining 3-Year Update Data from the CASPIAN Trial
    EP. 5: Predictors of Immunotherapy Response in Limited and Extensive SCLC
    EP. 6: Overcoming Immunotherapy Resistance in Small Cell Lung Cancer
    EP. 7: Examining the use of PD-L1 and tTMB in the CASPIAN Trial
    EP. 8: Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy
    EP. 9: Navigating Later-Line Therapy Sequencing in LS-SCLC Progression
    EP. 10: DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival
    EP. 11: Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC
    EP. 12: Examining Key Data from DAREON-8
    EP. 13: Closing Thoughts and Key Takeaways on Small Cell Lung Cancer
    1. In patients with LS-SCLC, what would you consider to be a reasonable time interval between completion of cCRT to initiation of consolidation therapy with a PD-L1 inhibitor?
      1. Please discuss your thoughts on the range of time prior to initiating therapy - from immediately to 6 weeks post-cCRT.
    2. What is the potential for curative-intent immunotherapy with durvalumab for earlier stages of SCLC?
      1. What is the role of SBRT in earlier stages of disease vs cCRT followed by durvalumab?
    x